Xavier Hernández‐Yagüe
Hospital Universitari de Girona Doctor Josep Trueta(ES)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, Gastric Cancer Management and Outcomes, Hepatocellular Carcinoma Treatment and Prognosis, Colorectal Cancer Surgical Treatments
Most-Cited Works
- → Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain(2006)83 cited
- → Stem cell property epithelial‐to‐mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild‐type tumor cells(2010)47 cited
- → Intersticial pneumonitis after oxaliplatin treatment in colorectal cancer(2005)45 cited
- → Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab(2013)23 cited
- → Xeroderma pigmentosum: neck lymph node metastasis of a squamous cell carcinoma of the skin treated with cetuximab(2009)23 cited
- → Is Metformin Associated With Improved Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer?(2021)16 cited
- → Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)(2022)15 cited
- → 511MO Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: The randomized phase II CITRIC trial(2024)12 cited
- → P-118 Cetuximab rechallenge in RAS, BRAF, EGFR-ECD wild type metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapies in first line: The CITRIC study(2022)7 cited
- → Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma(2012)6 cited